优化预防性辅助直线加速器(OPAL)放疗:每日部分乳腺照射的2期试验
这项2期试验评估了35 Gy分10次每日部分乳腺照射方案,对照全乳照射加推量,149例患者中主要毒性发生率为17.4%,对照为72.7%(P<.001),患者和医生报告的美观、功能状态和疼痛均改善。
要点
- OPAL试验中位随访2.0年,1例(0.7%)发生乳腺内复发。
- 主要毒性(≥2级)发生率OPAL组17.4%(26/149)vs 全乳照射加推量组72.7%(128/176),P<.001。
- OPAL方案与患者报告美观、功能状态、疼痛及医生报告美观改善相关。
核心结论
- 与全乳照射加推量相比,每日部分乳腺照射与早期毒性大幅降低及患者和医生报告结局改善相关。
- 作者认为每日外照射部分乳腺照射13次或更少的分割方案值得进一步前瞻性评估。
研究设计与样本
- 2期临床试验(OPAL试验),评估35 Gy分10次每日部分乳腺照射方案,切缘近(<2毫米)者加9 Gy分3次推量。
- 纳入行保乳术且切缘阴性、导管原位癌或雌激素受体阳性浸润性乳腺癌、肿瘤≤3厘米、pTis-T2 N0的患者。
- 主要终点为放疗开始至随访6个月内任何≥2级毒性效应;次要终点包括患者报告的美观、乳腺疼痛和功能状态(采用乳腺癌治疗结局量表)及医生报告的美观(采用放射治疗肿瘤学组量表)。
- 采用Cochran-Armitage趋势检验和多变量混合效应纵向生长曲线模型,将OPAL研究人群与接受全乳照射加推量的相似患者对照组进行比较。
主要发现
- OPAL试验全部149例患者均接受处方剂量,17.4%接受推量;中位年龄64岁;83.2%为白人,73.8%超重或肥胖。
- 中位随访2.0年,1例患者(0.7%)发生乳腺内复发。
- 主要毒性结局发生率OPAL试验为17.4%(26/149),全乳照射加推量对照组为72.7%(128/176),P<.001。
- 纵向多变量分析中,OPAL试验治疗与患者报告美观改善(P<.001)、功能状态改善(P=.004)、乳腺疼痛改善(P=.004)及医生报告美观改善(P<.001)相关。
关键数值与推荐
- OPAL方案:35 Gy分10次每日部分乳腺照射;切缘近(<2毫米)者加9 Gy分3次推量。
- 主要毒性结局发生率:OPAL组17.4%(26/149)vs 全乳照射加推量组72.7%(128/176),P<.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evidence supports use of partial-breast irradiation (PBI) in the management of early breast cancer, but the optimal dose-fractionation remains unsettled. METHODS AND MATERIALS: We conducted a phase 2 clinical trial (OPAL trial) to evaluate a novel PBI dosing schedule of 35 Gy in 10 daily fractions. Patients with close (<2 mm) margins also received a boost of 9 Gy in 3 fractions. Eligible patients underwent margin-negative lumpectomy for ductal carcinoma in situ or estrogen receptor-positive invasive breast cancer, up to 3 cm, pTis-T2 N0. The primary outcome was any grade ≥2 toxic effect occurring from the start of radiation through 6 months of follow-up. Secondary outcomes included patient-reported cosmesis, breast pain, and functional status, measured using the Breast Cancer Treatment Outcomes Scale, and physician-reported cosmesis, measured using the Radiation Therapy and Oncology Group scale. The Cochran-Armitage trend test and multivariable mixed-effects longitudinal growth curve models compared outcomes for the OPAL study population with those for a control group of similar patients treated with whole-breast irradiation (WBI) plus boost. RESULTS: All 149 patients enrolled on the OPAL trial received the prescribed dose, and 17.4% received boost. The median age was 64 years; 83.2% were White, and 73.8% were overweight or obese. With median follow-up of 2.0 years, 1 patient (0.7%) experienced in-breast recurrence. Prevalence of the primary toxicity outcome was 17.4% (26 of 149 patients) in the OPAL trial compared with 72.7% (128 of 176 patients) in the control WBI-plus-boost cohort (P < .001). In longitudinal multivariable analysis, treatment on the OPAL trial was associated with improved patient-reported cosmesis (P < .001), functional status (P = .004), breast pain (P = .004), and physician-reported cosmesis (P < .001). CONCLUSIONS: Treatment with daily PBI was associated with substantial reduction in early toxicity and improved patient- and physician-reported outcomes compared with WBI plus boost. Daily external-beam partial-breast irradiation with 13 or fewer fractions merits further prospective evaluation.
引用
- Reddy JP, Lei X, Bloom ES, et al. Optimizing Preventive Adjuvant Linac-Based (OPAL) Radiation: A Phase 2 Trial of Daily Partial Breast Irradiation. Int J Radiat Oncol Biol Phys. 2022. PMID: 36216274. doi:10.1016/j.ijrobp.2022.09.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。